Echo IQ signs partnership agreement with ScImage to distribute EchoSolv AI cardiac software

Go to Imelda Cotton author's page
By Imelda Cotton - 
EchoIQ ASX EIQ ScImage contract

Medical technology company Echo IQ (ASX: EIQ) has secured a partnership agreement with US-based ScImage Inc that will make its EchoSolv artificial intelligence (AI) medical software available to medical practitioners within the next three months.

The system aims to provide medical practitioners with access to high-quality, automated and AI-backed echocardiography assessments to assist in the management of this life-threatening but treatable condition.

ScImage provides medical enterprise cardiovascular information systems (CVIS), cloud-native enterprise image management, picture archiving and communication systems and image exchange solutions for the healthcare industry.

Software integration

Under the terms of the agreement, EchoSolv software will be integrated into ScImage’s PICOM365 cloud image management and reporting platform to enable faster and more accurate diagnoses of aortic stenosis.

It will be rolled out to key CVIS practices across the US, including cardiology practices and hospitals, before year-end.

The sites have been earmarked as potential generators of early revenue under a planned reimbursement model.

“ScImage is a trusted partner to many leading cardiology centres in the US and is recognised for its consistent innovation in cloud-native imaging solutions,” Echo IQ executive chair Andrew Grover said.

“We are honoured to have been selected as a decision support partner for cardiology reporting in an agreement that will see our proprietary AI-backed capabilities made available to forward-looking medical practitioners in the next three months.”

AI heart check

Echo IQ’s EchoSolv technology provides an AI-powered risk assessment of structural heart disease aimed at identifying at-risk patients who may benefit from further referral and reduce the risk of misdiagnosis.

The decision-support tool can help medical practitioners detect aortic stenosis and mitral regurgitation.

A flagship clinical trial in April 2023 showed EchoSolv could identify 72% more patients with severe aortic stenosis than human diagnosis alone.

The condition is reported to be one of the most common forms of heart valve disease in older people and is associated with high risks to life if not diagnosed and treated promptly.